Phenergan

Anaphylaxis, Catarrh, Acute Bronchitis + 18 more

Treatment

6 FDA approvals

20 Active Studies for Phenergan

What is Phenergan

Promethazine

The Generic name of this drug

Treatment Summary

Promethazine is a medication used to treat allergies, pain, sedation, nausea, and vomiting. It was first developed in France in 1946 and approved by the FDA in 1951. Promethazine works by blocking certain receptors in the body, allowing it to work on a variety of indications.

Phenergan

is the brand name

image of different drug pills on a surface

Phenergan Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Phenergan

Promethazine

1951

473

Approved as Treatment by the FDA

Promethazine, otherwise called Phenergan, is approved by the FDA for 6 uses such as Nasal Congestion and Acute Bronchitis .

Nasal Congestion

Used to treat Nasal Congestion in combination with Phenylephrine

Acute Bronchitis

Used to treat Cough in combination with Dextromethorphan

Hypersensitivity

Used to treat Allergic Reaction in combination with Codeine

Anaphylaxis

Catarrh

Used to treat Common Cold in combination with Codeine

upper respiratory symptoms

Used to treat upper respiratory symptoms in combination with Codeine

Effectiveness

How Phenergan Affects Patients

Promethazine is a medicine that helps to reduce pain, induce sleepiness, and treat allergies. The effects of the drug last for 4-6 hours, but may last up to 12 hours. Patients should be aware of the potential risks such as reduced alertness or breathing, increased risk of seizures, and decreased production of red blood cells.

How Phenergan works in the body

Promethazine helps reduce allergic reactions, improve sleep, manage anxiety and tension, and reduce nausea and vomiting. It does this by blocking certain receptors in the body, including histamine H1, dopamine, alpha adrenergic, muscarinic, and NMDA receptors.

When to interrupt dosage

The suggested dosage of Phenergan is contingent upon the determined condition, including Hay Fever, Postoperative Pain and Acute Bronchitis. The amount of dosage is reliant on the approach of administration set out in the table below.

Condition

Dosage

Administration

Hypersensitivity

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Allergic urticaria

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Sedative therapy

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Allergic Conjunctivitis (AC)

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Postoperative Pain

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

upper respiratory symptoms

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Analgesics

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Hay Fever

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Coughing

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Nasal Congestion

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Motion Sickness

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Acute Bronchitis

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Nausea

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Dermographism

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

perioperative nausea and vomiting

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Airsickness

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Rhinitis, Vasomotor

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Anaphylaxis

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Hypersensitivity

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Catarrh

, 12.5 mg, 25.0 mg, 50.0 mg, 6.25 mg/mL, 25.0 mg/mL, 50.0 mg/mL, 0.25 mg, 0.5 mg/mL, 1.0 mg/mL, 0.625 mg/mL, 6.5 mg/mL, 10.0 mg, 2.0 %, 10.0 mg/mL, 28.2 mg/mL, 3.125 mg/mL

Oral, Tablet - Oral, Tablet, , Syrup - Oral, Syrup, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Rectal, Suppository, Suppository - Rectal, Injection, Injection - Intramuscular; Intravenous, Intramuscular, Injection - Intramuscular, Liquid, Liquid - Oral, Solution - Oral, Solution, Capsule, Capsule - Oral, Intravenous, Injection, solution - Intravenous, Injection, solution - Intramuscular, Cream, Cream - Topical, Solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Topical

Warnings

Phenergan Contraindications

Condition

Risk Level

Notes

subcutaneous route of administration

Do Not Combine

Asthma

Do Not Combine

Pulse Frequency

Do Not Combine

intra-arterial route of administration

Do Not Combine

Coma

Do Not Combine

lower respiratory tract symptoms

Do Not Combine

There are 20 known major drug interactions with Phenergan.

Common Phenergan Drug Interactions

Drug Name

Risk Level

Description

Acenocoumarol

Major

The metabolism of Acenocoumarol can be decreased when combined with Promethazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Promethazine is combined with Aclidinium.

Amisulpride

Major

Promethazine may increase the antipsychotic activities of Amisulpride.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Promethazine.

Azelastine

Major

Promethazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Phenergan Toxicity & Overdose Risk

The lowest toxic dose of promethazine in rats and mice is 170mg/kg and 160mg/kg intraperitoneally, and 400mg/kg and 240mg/kg subcutaneously. Taking too much promethazine can cause mild mental and heart problems, low blood pressure, slow breathing, loss of consciousness, stiff muscles, twitches, seizures, dry mouth, redness of the face, stomach problems, and a fixed gaze. Treating an overdose may involve taking activated charcoal, sulfates, controlled ventilation, diazepam, fluids, drugs to increase blood pressure, anti-Parkinson medications, diphenhyd

image of a doctor in a lab doing drug, clinical research

Phenergan Novel Uses: Which Conditions Have a Clinical Trial Featuring Phenergan?

131 active clinical trials are currently examining the potential of Phenergan in providing Allergy relief, Sedative therapy and Hay Fever mitigation.

Condition

Clinical Trials

Trial Phases

Anaphylaxis

3 Actively Recruiting

Phase 1, Phase 2

Rhinitis, Vasomotor

1 Actively Recruiting

Not Applicable

Motion Sickness

0 Actively Recruiting

Analgesics

1 Actively Recruiting

Phase 4

Catarrh

0 Actively Recruiting

Nausea

0 Actively Recruiting

Dermographism

0 Actively Recruiting

Acute Bronchitis

8 Actively Recruiting

Phase 4, Not Applicable, Phase 3, Early Phase 1

upper respiratory symptoms

0 Actively Recruiting

Postoperative Pain

20 Actively Recruiting

Phase 4, Phase 2, Phase 1, Phase 3, Not Applicable

Allergic urticaria

0 Actively Recruiting

perioperative nausea and vomiting

0 Actively Recruiting

Sedative therapy

0 Actively Recruiting

Pain management

0 Actively Recruiting

Nasal Congestion

0 Actively Recruiting

Hypersensitivity

1 Actively Recruiting

Phase 4

Allergic Conjunctivitis (AC)

0 Actively Recruiting

Hay Fever

0 Actively Recruiting

Hypersensitivity

0 Actively Recruiting

Airsickness

2 Actively Recruiting

Not Applicable, Phase 3

Phenergan Reviews: What are patients saying about Phenergan?

5

Patient Review

1/11/2014

Phenergan for Feel Like Throwing Up

I stopped taking this medication after only two days because it made me feel worse. I was constantly dizzy and sick, and couldn't keep anything down. It took a few more days to start feeling better, but I'm still dealing with some balance and dizziness issues.

5

Patient Review

8/17/2013

Phenergan for Nausea and Vomiting

I had anaphylactic response and went to the ER as a result. Swelling made it difficult to speak or breathe.

5

Patient Review

3/27/2017

Phenergan for Nausea and Vomiting

This was the only treatment that gave me relief when I had the stomach flu!

5

Patient Review

12/27/2012

Phenergan for Nausea and Vomiting

5

Patient Review

3/16/2014

Phenergan for Nausea and Vomiting

If you want this treatment to work, be sure to take it at least three or four hours before your planned bedtime.

4.3

Patient Review

3/14/2014

Phenergan for Nausea and Vomiting

Unfortunately, this patient has become more confused since being administered this drug. We've seen a significant worsening of symptoms for several days before they begin to improve again. This was given as an injection, and it's worth noting that the patient had a stroke four months ago. Has anyone else experienced something similar?

4.3

Patient Review

5/22/2018

Phenergan for Throwing Up

This medicine helped with my morning sickness a lot. The only downside is that it made me sleepy.

4.3

Patient Review

11/21/2013

Phenergan for Nausea and Vomiting

Helped me a lot with my runny nose and throwing up.

4

Patient Review

5/11/2014

Phenergan for Nausea and Vomiting

Phenergan was incredibly effective in taking care of my Norovirus symptoms and helping me get the rest I needed to recover.

3.7

Patient Review

11/27/2016

Phenergan for Nausea and Vomiting

The patient became severely confused about time and place. They had no memory of events that occurred 15 minutes to one day prior.

3.7

Patient Review

1/24/2014

Phenergan for Chronic Trouble Sleeping

It effectively eliminates my nausea and provides a sense of calm.

3.3

Patient Review

6/16/2013

Phenergan for Runny Nose

2.7

Patient Review

6/11/2014

Phenergan for Nausea and Vomiting of Pregnancy

Less than an hour after being given this medication following surgery, I had to go to the emergency room due to blurred vision and loss of consciousness.

2.3

Patient Review

5/23/2021

Phenergan for Nausea and Vomiting

This medication helped with my nausea and stomach pain. However, I soon after felt incredibly confused, dizzy, and unbalanced to the point where I couldn't communicate. It was practically a full on catatonic state. While it helped it was not worth the side effects.

2.3

Patient Review

5/11/2014

Phenergan for Nausea and Vomiting After Surgery

Cannot recommend this drug.

2.3

Patient Review

4/17/2013

Phenergan for Runny Nose

1

Patient Review

9/14/2019

Phenergan for Itching

My 85 year old father took just one 25mg tablet of this at 10pm last night. All the following day he has been extremely drowsy, has had very bad slurred speech, and loss of coordination. Very bed experience altogether!

1

Patient Review

8/8/2013

Phenergan for Motion Sickness

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about phenergan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Why does Phenergan make you sleepy?

"Promethazine blocks histamine receptors in the brain, which reduces symptoms. It also crosses the blood-brain barrier in large quantities, which can make you feel drowsy. Promethazine also blocks dopamine receptors, which prevents nausea."

Answered by AI

Is Phenergan a sedative?

"Phenergan may cause drowsiness in some people. A single dose may still affect you in the morning. Children and the elderly are especially sensitive to the effects of antihistamines."

Answered by AI

Is Phenergan good for sleep?

"Phenergan Night Time works by blocking histamine to help with insomnia and by working directly on the brain to help you feel more relaxed."

Answered by AI

What is a Phenergan used for?

"Phenergan Tablets are used as a short-term sleep aid for adults with difficulty sleeping, and to treat hay fever or hives in adults and children. They can also be used to treat nausea and vomiting, such as travel sickness."

Answered by AI

Clinical Trials for Phenergan

Image of University Center for Ambulatory Surgery in Somerset, United States.

Infusion Pump for Postoperative Pain

18+
All Sexes
Somerset, NJ

This study will be a pragmatic, prospective cluster randomized trial, where clusters will formed based on sequential 2 week time increments across the study recruitment period.. Patients 18 years or older undergoing ACL reconstruction, open shoulder labrum or rotator cuff surgery, arthroscopic rotator cuff repair, proximal or distal patellar realignment surgery, open knee arthrotomy cases (i.e. inside out meniscus repair, osteochondral allograft transplantation (OCA), meniscal allograft transplantation (MAT)) at University Center for Ambulatory Surgery, LLC (UOA) will be reviewed for eligibility. Once identified, potential study subjects will be asked whether they are interested in participating in the project. If the patient agrees, the subject will be given the informed consent to read and sign. Objectives: The primary objective is to compare the effectiveness of postoperative infusion pain pump versus preoperative nerve block in reducing visual analog pain scores/numerical pain rating scale (VAS/NPRS) in the postoperative period. The second objective is to evaluate the requirement of narcotic and non-narcotic analgesic medications between the two groups. Hypotheses: Use of continuous infusion pain pump or single shot peripheral block will result in similar post-operative pain control after outpatient sports medicine surgical cases.

Phase 4
Recruiting

University Center for Ambulatory Surgery

Image of Cedars-Sinai Medical Center Otolaryngology Clinics in Los Angeles, United States.

Lavender Aromatherapy for Anxiety and Pain During Otolaryngologic Procedures

18+
All Sexes
Los Angeles, CA

The purpose of this study is to evaluate the efficacy of lavender aromatherapy in adult patients undergoing awake otolaryngologic procedures in the outpatient clinic setting. The main questions it aims to answer are: * Does lavender aromatherapy help reduce anxiety and/or pain, and improve patient comfort during awake otolaryngologic procedures in the clinic? * Do patients subjectively find aromatherapy relaxing and/or beneficial during the procedure? Researchers will compare lavender aromatherapy to placebo (an odorless liquid) to see if lavender aromatherapy helps improve patient comfort during their awake procedure Participants will: * Have their scheduled procedure performed with lavender aromatherapy or placebo during the duration of the procedure * Take a short, less than 1 minute questionnaire both before and after the procedure, describing their levels of anxiety, pain and subjective impressions of the aromatherapy

Recruiting
Paid Trial

Cedars-Sinai Medical Center Otolaryngology Clinics

Ankona Ghosh, MD

Have you considered Phenergan clinical trials?

We made a collection of clinical trials featuring Phenergan, we think they might fit your search criteria.
Go to Trials
Image of UI Health Care Center for Advanced Reproductive Care in Iowa City, United States.

Ketorolac for Infertility Treatment

18 - 37
Female
Iowa City, IA

Ketorolac is a medication often used to relieve pain after surgery. In the past, infertility doctors have been cautious about using ketorolac after egg retrieval for patients planning a fresh embryo transfer (usually done 5 days later). The concern was that ketorolac might increase the risk of bleeding or reduce the chances of the embryo implanting in the uterus. This concern comes from how ketorolac works-it blocks certain chemicals in the body (like prostaglandins and thromboxane) that help with blood clotting and play a role in early pregnancy. However, a large review of past studies found no real evidence that ketorolac increases bleeding risk. In fact, ketorolac is now routinely used for pain relief in IVF cycles where embryos are frozen and not transferred right away. More recent studies from Boston and Chapel Hill have shown that ketorolac provides better pain control and does not appear to harm IVF outcomes, even when embryos are transferred fresh (within the same cycle). Despite these encouraging findings, many IVF clinics still avoid using ketorolac during fresh cycles because of the theoretical concerns. That's why we need stronger, higher-quality research. This study aims to fill that gap by conducting a double-blind randomized controlled trial to find out whether giving ketorolac through an IV after egg retrieval affects important IVF outcomes-especially the chance of implantation and live birth-in patients undergoing fresh embryo transfers. Patients who choose to join the study will randomly be placed into one of two groups. One group will get ketorolac (a pain medicine) after an IVF egg retrieval. The other group will not get ketorolac after egg retrieval. Everything else in their IVF care will stay the same as it normally would. Primary outcome will be implantation rate following fresh embryo transfers in patients receiving ketorolac (30mg IV) vs no ketorolac for post-retrieval analgesia. Secondary outcomes will include pain scale, narcotics required, time to discharge, need for evaluation w/in 24 hours for pain/bleeding, clinical pregnancy rates, miscarriage rates, and live birth rates following fresh embryo transfers in patients receiving ketorolac vs no ketorolac for post-retrieval analgesia.

Phase 4
Recruiting

UI Health Care Center for Advanced Reproductive Care

Have you considered Phenergan clinical trials?

We made a collection of clinical trials featuring Phenergan, we think they might fit your search criteria.
Go to Trials
Image of Thomas Jefferson University in Philadelphia, United States.

Physical Therapy for Ventral Hernia

18 - 75
All Sexes
Philadelphia, PA

The goal of this clinical trial is to evaluate the efficacy, safety, and cost-effectiveness of a tailored physical therapy (PT) intervention targeting Abdominal Core Health components in patients recovering from ventral hernia repair. The study focuses on patients aged 18-75 diagnosed with a ventral transverse hernia between 4 cm and 10 cm, scheduled for elective Ventral Hernia Repair (VHR). The main questions it aims to answer are: * Will tailored PT significantly improve abdominal core strength, biomechanical stability, and functional mobility compared to usual care at 3-months post-surgery? * Will tailored PT lead to higher patient-reported quality of life and satisfaction scores, with a lower incidence of post-operative complications such as bowel obstruction and pelvic floor dysfunction over a 1-year follow-up? * Will tailored PT result in decreased healthcare utilization, leading to overall cost savings or neutrality compared to usual care over the first year after VHR? Researchers will compare the tailored physical therapy group to a usual care group to see if the tailored intervention leads to significant improvements in clinical efficacy, patient outcomes, and cost-effectiveness. Participants will: * Be randomly assigned to either the Usual Care Group or the PT Group. * If in the Usual Care Group, receive standard post-operative instructions for 12 weeks, including guidance on binder use, safe lifting, and gradual return to activities. * If in the PT Group, receive foundational post-operative instructions for the first 2 weeks (similar to usual care). Undergo 6 structured and individualized PT sessions over 10 weeks if in the PT Group, with progression based on Oswestry Disability Index (ODI) and Pelvic Floor Distress Inventory-20 (PFDI-20) scores, including Symptom Modulation, Movement Control, Functional Optimization, or Impairment-Based interventions. Participants undergo data collection at 2 weeks, 12 weeks, and 1 year post-operation, including imaging, functional mobility tests, pain scales, patient-reported outcomes, physical measurements, and tracking of complications and healthcare utilization. Participate in semi-structured interviews after the 12-week assessment to provide qualitative insights into their experiences and perceived barriers/facilitators.

Waitlist Available
Has No Placebo

Thomas Jefferson University

Christopher Keating

Image of Rutgers School of Dental Medicine in Newark, United States.

Temporo-masseteric Nerve Block for Postoperative Pain

18+
All Sexes
Newark, NJ

The proposed design is a triple-blind, placebo-controlled randomized prospective phase II trial to assess the feasibility of employing the Temporo-masseteric Nerve Block (TMNB) injection to decrease jaw muscle pain, overall pain, improve mouth opening and minimize pain medication consumption. 80 participants undergoing lower third molar removal under sedation will be enrolled. Those who develop significant jaw muscle pain on the following day will be randomized to receive either the TMNB injection or a placebo. Daily ecological momentary assessments (EMAs) will be collected reflecting elements of patient experience for all participants. On Day 8, participants return for an end-of-study evaluation and return their unused pain medications. Up to 40 participants who are randomized to receive TMNB/placebo will be recruited to participate in a qualitative interview regarding their experience.

Phase 2
Waitlist Available

Rutgers School of Dental Medicine

Have you considered Phenergan clinical trials?

We made a collection of clinical trials featuring Phenergan, we think they might fit your search criteria.
Go to Trials